



Description:	Rabbit anti-MEK1/2
Catalogue#:	500-7854
Lot#:	See the label
Size:	100 ug/200 ul
Host:	Rabbit
Clone:	N/A
Application:	ELISA, WB
Reactivity:	Hu, Ms, Rt, Ck

# AbboMax, Inc

Innovation at Work

## Rabbit anti MEK1/2 Antibody

Alternate Names: MAPKK1/2, MEK1/2.

### ANTIGEN PREPARATION

A synthetic peptide corresponding to internal sequence of human MEK1/2. This sequence is identical among human, rat, mouse, chicken.

### BACKGROUND

The MEK1 & 2 (MAPKK1/2) are members of tyrosine/threonine protein kinase family that activate the ERK1+2/MAPK enzymes by phosphorylation. MEK 1 + 2 are also activated by dual-phosphorylation, which occurs on serine 218 and 222, in the activation loop of the MEKs. The MEK1 & 2 are regulated by phosphorylation by one of the MEK kinases.

### PURIFICATION

The Rabbit IgG is purified by Site-specific Epitope Affinity Purification.

### SPECIFICITY

This antibody recognizes ~44/45 kDa of human MEK1/2 protein. This antibody also reacts with mouse and rat, chicken. The other species are not tested.

### FORMULATION

This affinity purified antibody is supplied in sterile Phosphate-buffered saline (pH7.2) containing antibody stabilizer

### STORAGE

The antibodies are stable for 12 months from date of receipt when stored at -20°C to -70°C. The antibodies can be stored at 2°C-8°C for three month without detectable loss of activity. Avoid repeated freezing-thawing cycles.


### APPLICATIONS/SUGGESTED WORKING DILUTIONS

Western Blot	0.1-1 µg/ml
ELISA	0.01-0.1 µg/ml
Immunoprecipitation	2-5 µg/ml
IHC	Not tested
Flow cytometry	Not tested

<b>MOLECULAR WEIGHT:</b>	44 kDa
<b>POSITIVE CONTROL:</b>	3T3
<b>CELLULAR LOCATION:</b>	N/A

Optimal dilutions should be determined by researchers for the specific applications.

### DATA ATTACHMENTS



**Western Blot:**  
The whole cell lysates derived from 3T3 were immunoblotted by Rabbit anti-MEK1/2 (Cat#500-7854) at 1:1000 .

### REFERENCES

Ali R. Jazirehi, et al. Inhibition of the Raf-MEK1/2-ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin's Lymphoma B Cells by Rituximab. CANCER RESEARCH 64, 7117-7126, October 1, 2004

**FOR RESEARCH USE ONLY.**